



Curriculum Vitae

Personal information **Anna Sundlöv**

Work experience

1. Employer: Swedish Medical Products Agency
 - Start date: 042021
 - End date: present
 - Position: Clinical Assessor
 - Activities: Assessment of applications for clinical trials and special permissions, primarily in oncology. National expert on radionuclide therapy and radiopharmaceuticals. Swedish representative in SAMIRA (Strategic Agenda for Medical Ionising Radiation Applications).
 - Country: Sweden
2. Employer: Lund University
 - Start date: 012019
 - End date: 122022
 - Position: Researcher
 - Activities: Supervision of PhD_students in research projects within the areas of radionuclide therapy and endocrine tumors.
 - Country: Sweden
3. Employer: Skåne University Hospital
 - Start date: 042010
 - End date: 032021
 - Position: Senior Consultant in Oncology
 - Activities: Head of the Unit for Endocrine Tumors and Radionuclide Therapy
 - Country: Sweden
4. Employer: Synapticon AB
 - Start date: 102018
 - End date: 032021
 - Position: Founder and Senior Consultant
 - Activities: Consulting services for small and medium_sized pharmaceutical companies, CROs, academic research groups and others who need part_time or project_based consultation in designing clinical trials, medical writing, medical monitoring or training in any of the areas of expertise (oncology, radionuclide therapy, clinical trials).
 - Country: Sweden
5. Employer: Novartis Oncology
 - Start date: 072006
 - End date: 052009
 - Position: Medical Advisor
 - Activities: Responsible for the internal and external scientific advice. Management on a national level of international clinical trials phase I_IV including critical protocol review, feasibility feed_back, site selection, lead investigator meetings, negotiations with cooperative groups and CROs, initiate action plans, etc.
 - Country: Spain
6. Employer: La Paz University Hospital
 - Start date: 072001
 - End date: 062006
 - Position: Resident physician Medical Oncology
 - Activities:
 - Country: Spain

Education and training

1. Subject: Lund University
 - Start date: 082012
 - End date: 022020
 - Qualification: PhD
 - Organisation: PhD thesis entitled "Tailoring Radionuclide Therapy of Neuroendocrine Tumors"
 - Country: Sweden
2. Subject: La Paz University Hospital
 - Start date: 072001
 - End date: 062006
 - Qualification: Specialist in Oncology
 - Organisation:
 - Country: Spain
3. Subject: Karolinska Institutet
 - Start date: 011992
 - End date: 101998
 - Qualification: Medical Degree in Medicine and Surgery
 - Organisation:
 - Country: Sweden

Additional information

Publications

- Dosimetric quantities of neuroendocrine tumors over treatment cycles with ¹⁷⁷Lu_DOTA_TATE Roth, D., Gustafsson, J., Warfvinge, C. F., Sundlöv, A., Åkesson, A., Tennvall, J. & Sjögreen Gleisner, K., 2022 Mar, In: *Journal of Nuclear Medicine*. 63, 3, p. 399_405 7 p.
- Increased risk of Graves' ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres Shahida, B., Tsoumani, K., Planck, T., Modhukur, V., Asp, P., Sundlöv, A., Tennvall, J., Åsman, P., Lindgren, O. & Lantz, M., 2022, In: *Endocrine*. 75, 3, p. 856_864
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry_based ¹⁷⁷Lu_DOTATATE treatment of NET patients Sundlöv, A., Gleisner, K. S., Tennvall, J., Ljungberg, M., Warfvinge, C. F., Holgersson, K., Hallqvist, A., Bernhardt, P. & Svensson, J., 2022, In: *European Journal of Nuclear Medicine and Molecular Imaging*. 49, 11, p. 3830_3840
- Relationship between somatostatin receptor expressing tumour volume and health_related quality of life in patients with metastatic GEP_NET Ohlsson, H., Gålne, A., Trägårdh, E., Malmström, M., Sundlöv, A. & Almquist, M., 2022, In: *Journal of Neuroendocrinology*. 34, 6
- The molecular characteristics of high_grade gastroenteropancreatic neuroendocrine neoplasms Venizelos, A., Elvebakken, H., Perren, A., Nikolaienko, O., Deng, W., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlöv, A., Svensson, J. B., Garresori, H., Kersten, C., Hofslie, E., Detlefsen, S., Krogh, M., Sorbye, H. & Knappskog, S., 2021 Oct 1, (E_pub ahead of print) In: *Endocrine-Related Cancer*.
- Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours Ohlsson, H., Wahlberg, G., Malmström, M., Gustafsson, R., Sundlöv, A., Nordenström, E. & Almquist, M., 2021 May 9, (E_pub ahead of print) In: *World Journal of Surgery*.
- Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment Sundlöv, A. & Sjögreen_Gleisner, K., 2021 Feb 1, In: *Clinical Oncology*. 33, 2, p. 92_97 6 p. Dosimetric quantities of neuroendocrine tumors over treatment cycles with ¹⁷⁷Lu_DOTA_TATE Roth, D., Gustafsson, J., Warfvinge, C. F., Sundlöv, A., Åkesson, A., Tennvall, J. & Sjögreen Gleisner, K., 2021, (E_pub ahead of print) In: *Journal of Nuclear Medicine*. 62, 10
- Surgery of the primary tumour in 201 patients with high_grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine_non_neuroendocrine neoplasms Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlöv, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., 2021, (E_pub ahead of print) In: *Journal of Neuroendocrinology*.
- Pituitary function after high_dose ¹⁷⁷Lu_DOTATATE therapy and long_term follow_up Sundlöv, A., Sjögreen_Gleisner, K., Tennvall, J., Dahl, L., Svensson, J., Åkesson, A., Bernhardt, P. & Lindgren, O., 2020 Apr 8, (E_pub ahead of print) In: *Neuroendocrinology*. Characterisation of a hand_held CZT_based gamma camera for ¹⁷⁷Lu imaging Roth, D., Larsson, E., Sundlöv, A. & Sjögreen Gleisner, K., 2020, In: *EJNMMI Physics*. 7, 1, 46.
- Tailoring Radionuclide Therapy of Neuroendocrine Tumors _ Bridging the Gaps Sundlöv, A., 2020, Lund: Lund University, Faculty of Medicine. 97 p.
- A prospective observational study to evaluate the effects of long_acting somatostatin analogs on ⁶⁸Ga_DOTATATE uptake in patients with neuroendocrine tumors Gålne, A., Almquist, H., Almquist, M., Hindorf, C., Ohlsson, T., Nordenström, E., Sundlöv, A. & Trägårdh, E., 2019, In: *Journal of Nuclear Medicine*. 60, 12, p. 1717_1723
- Bone marrow absorbed doses and correlations with hematological response during ¹⁷⁷Lu_DOTATATE treatments are influenced by image_based dosimetry method and presence of skeletal metastases Hagmarker, L., Svensson, J., Ryden, T., van Essen, M., Sundlöv, A., Sjögreen Gleisner, K., Gjertsson, P. & Bernhardt, P., 2019, In: *Journal of Nuclear Medicine*. 60, 10, p. 1406_1413
- The Effect of Radioiodine Treatment on TRAb, Anti_TPO, and Anti_TG in Graves' Disease Lindgren, O., Asp, P., Sundlöv, A., Tennvall, J., Shahida, B., Planck, T., Åsman, P. & Lantz, M., 2019, In: *European Thyroid Journal*. 8, 2, p. 64_69 Feasibility of simplifying renal dosimetry in ¹⁷⁷Lu peptide receptor radionuclide therapy Sundlöv, A., Gustafsson, J., Brolin, G., Mortensen, N., Hermann, R., Bernhardt, P., Svensson, J., Ljungberg, M., Tennvall, J. & Sjögreen Gleisner, K., 2018 Dec 1, In: *EJNMMI Physics*. 5, 1, 12.
- Quantitative analysis of phantom studies of ¹¹¹In and ⁶⁸Ga imaging of neuroendocrine tumours Jönsson, L., Stenvall, A., Mattsson, E., Larsson, E., Sundlöv, A., Ohlsson, T. & Hindorf, C., 2018 Dec 1, In: *EJNMMI Physics*. 5, 1, 5.
- A method for tumor dosimetry based on hybrid planar_SPECT/CT images and semiautomatic segmentation Roth, D., Gustafsson, J., Sundlöv, A. & Sjögreen Gleisner, K., 2018 Nov, In: *Medical Physics*. 45, 11, p. 5004_5018 Health_Related Quality of Life After Surgery for Small Intestinal Neuroendocrine Tumours Milanetto, A. C., Nordenström, E., Sundlöv, A. & Almquist, M., 2018, In: *World Journal of Surgery*. 42, 10, p. 3231_3239
- SPECT image segmentation for estimation of tumour volume and activity concentration in ¹⁷⁷Lu_DOTATATE radionuclide therapy Gustafsson, J., Sundlöv, A. & Sjögreen Gleisner, K., 2017 Dec 1, In: *EJNMMI Research*. 7, 1, 18.
- Individualised ¹⁷⁷Lu_DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry Sundlöv, A., Sjögreen_Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T. G., Bernhardt, P. & Tennvall, J., 2017, In: *European Journal of Nuclear Medicine and Molecular Imaging*. 44, 9, p. 1480_1489
- Long_term retention of ¹⁷⁷Lu/¹⁷⁷mLu_Dotatate in patients investigated by gamma spectrometry and gamma camera imaging. Sjögreen Gleisner, K., Brolin, G., Sundlöv, A., Mjekiqi, E., Östlund, K., Tennvall, J. & Larsson, E., 2015, In: *Journal of Nuclear Medicine*. 56, 7, p. 976_984
- Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Gronbaek, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin_Jantti, C., Sundin, A., Sundlöv, A., Thiis_Evensen, E. & Knigge, U., 2014, In: *Acta Oncologica*. 53, 10, p. 1284_1297
- The role of RANK_ligand inhibition in cancer: the story of denosumab Castellano, D., Sepulveda, J. M., García_Escobar, I., Rodríguez_Antolín, A., Sundlöv, A. & Cortes_Funes, A., 2011, In: *The Oncologist*. 16, 2, p. 136_145 Bacteriemia por *Acinetobacter ursingii* Romero_Gómez, M. P., Sundlov, A., Sáez_Nieto, J. A., Álvarez, D. & Peña, P., 2006, In: *Enfermedades Infecciosas y Microbiología Clínica*. 24, 8, p. 535_536 2 p.
- Docetaxel and mitomycin as second_line treatment in advanced non_small cell lung cancer Feliiu, J., Martín, G., Castro, J., Sundlov, A., Rodríguez_Jaráz, A., Casado, E., Lomas, M., Madroñal, C., Galán, A., Belda, C. & Gonzalez_Barón, M., 2006, In: *Cancer Chemotherapy and Pharmacology*. 58, 4, p. 527_531 5 p. Treatment options for colorectal cancer in the elderly Feliiu, J., Castro, J., Belda, C., Sundlov, A., Casado, E. & González_Barón, M., 2006, In: *Aging and Mental Health*. 2, 6, p. 931_942 12 p.
- Anticuerpos contra el cáncer Barriuso Feijóo, J., Sundlov, A. & González Barón, M., 2004, In: *Revista Clínica Espanola*. 204, 12, p. 649_654 6 p.

Projects

CLINICAL TRIALS AS PRINCIPAL INVESTIGATOR

VISION _ an international, prospective, open_label, multicenter, randomized phase 3 study of 177Lu_PSMa_617 in the treatment of patients with progressive psma_positive metastatic castration_resistant prostate cancer (mCRPC)

BAY 2287411 _ First_in_human phase I trial of a thorium_227 labeledantibody_chelator conjugate, in patients with tumors known to express mesothelin

ILUMINET _ an academic phase II trial of safety and efficacy of Lu177_DOTATATE treatment of neuroendocrine tumors

GAPETTO _ an academic, prospective trial on the use of Ga68_DOTATATE_PET in patients with neuroendocrine tumors BASKET - a phase II trial in a selected number of solid tumors to investigate safety and efficacy of lurbinectidine

COOPERATE_2 _ an international randomized phase II trial of safety and efficacy of everolimus +/-pasireotide in patients with pancreatic neuroendocrine tumors

LUNA _ an international randomized phase II trial of safety and efficacy of everolimus +/-pasireotide in patients with carcinoid tumors of the lung and thymus

NORDIC GI_NEC _ a Nordic collaborative prospective registry study of the treatment of gastrointestinal neuroendocrine carcinomas

NORDIC ET_NEC _ a Nordic collaborative prospective trial of everolimus in combination with temozolomide in advanced/metastatic gastrointestinal neuroendocrine carcinoma

CLINICAL TRIALS AS SUB_INVESTIGATOR

EXAMINER -an international phase III trial of cabozantinib in medullary thyroid cancer

TELESTAR _Telotristat Etiprate for Somatostatin analogue refractory carcinoid syndrome

SELECT _ an international, randomised phase III trial of lenvatinib in iodine_refractory differentiated thyroid cancer

ALFARADIN _ Ra223 for the treatment of castration resistant prostate cancer with bone metastasis

ASTRA _ a randomised,double_blind, placebo_controlled study comparing selumetinib plus radioiodine vs radioiodine alone in patients with newly diagnosed high_risk differentiated thyroid cancer

DECISION _ an international, randomised, phase III trial of sorafenib in radioactive iodine_refractory, locally advanced or metastatic differentiated thyroid cancer

CLINICAL TRIALS Author/ co_author

START_NET _ Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open_label, multi_center, randomized controlled trial comparing safety and efficacy of personalized vs non_personalized radionuclide therapy with 177Lu_DOTATOC NORDIC

ET_NEC _ A Nordic collaborative prospective trial of everolimus in combination with temozolomide in advanced/metastatic gastrointestinal neuroendocrine carcinoma

ILUMINET _ an academic phase II trial of safety and efficacy of Lu177_DOTATATE treatment of neuroendocrine tumors

GAPETTO _ an academic, prospective trial on the use of Ga68_DOTATATE_PET in patients with neuroendocrine tumors

RAPTOR _ Open_label phase II trial of everolimus monotherapy for patients with advanced papillary renal cell cancer

Memberships

Member of the European Association of Nuclear Medicine (EANM)

Other Relevant Information